Synergistic antitumor activity of afatinib and nintedanib through PP2A reactivation in non-small-cell lung cancer cells

被引：1
|
作者：
Chao, T. -T. [1 ]
Chen, C. -H. [2 ]
Peng, Z. -A. [3 ]
Wang, C. -Y. [2 ]
机构：
[1] Cardinal Tien Hosp, Med Res Ctr, Taipei, Taiwan
[2] Cardinal Tien Hosp, Dept Internal Med, Taipei, Taiwan
[3] Cardinal Tien Hosp, Dept Pharm, Taipei, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(16)30195-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
82P
引用
收藏
页码：S90 / S90
页数：1
相关论文
共 50 条
  • [1] Afatinib and chemotherapy in non-small-cell lung cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (02): : E47 - E47
  • [2] Nintedanib for the treatment of non-small-cell lung cancer
    Rashdan, Sawsan
    Hanna, Nasser
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (05) : 729 - 739
  • [3] Afatinib in advanced non-small-cell lung cancer
    Di Maio, Massimo
    Gridelli, Cesare
    Grossi, Francesco
    Novello, Silvia
    de Marinis, Filippo
    LUNG CANCER MANAGEMENT, 2013, 2 (06) : 493 - 504
  • [4] Afatinib for the treatment of advanced non-small-cell lung cancer
    Genova, Carlo
    Rijavec, Erika
    Barletta, Giulia
    Burrafato, Giovanni
    Biello, Federica
    Dal Bello, Maria Giovanna
    Coco, Simona
    Truini, Anna
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (06) : 889 - 903
  • [5] Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer
    Liu, Zi
    Ma, Liang
    Wen, Zhe-Sheng
    Hu, Zheng
    Wu, Fu-Qun
    Li, Wei
    Liu, Jinsong
    Zhou, Guang-Biao
    CARCINOGENESIS, 2014, 35 (04) : 905 - 914
  • [6] Afatinib (BIBW 2992) development in non-small-cell lung cancer
    Hirsh, Vera
    FUTURE ONCOLOGY, 2011, 7 (07) : 817 - 825
  • [7] Nintedanib for the treatment of patients with advanced non-small-cell lung cancer
    Reck, Martin
    Heigener, David
    Reinmuth, Niels
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (05) : 579 - 590
  • [8] Clinical development of nintedanib for advanced non-small-cell lung cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1701 - 1706
  • [9] Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
    Shizuko Sei
    Jodie K Mussio
    Quan-en Yang
    Kunio Nagashima
    Ralph E Parchment
    Matthew C Coffey
    Robert H Shoemaker
    Joseph E Tomaszewski
    Molecular Cancer, 8
  • [10] Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
    Sei, Shizuko
    Mussio, Jodie K.
    Yang, Quan-en
    Nagashima, Kunio
    Parchment, Ralph E.
    Coffey, Matthew C.
    Shoemaker, Robert H.
    Tomaszewski, Joseph E.
    MOLECULAR CANCER, 2009, 8
12345